NOTCH1 and breast carcinoma: In vitro studies using ER+ breast cancer lines provided the initial evidence that Notch activation contributes to resistance to endocrine therapy and that targeting Notch1 or Notch4 by using genetic or pharmacologic means reversed this resistance.